Literature DB >> 24813570

Gender and injuries predict stimulant medication use.

Søren Dalsgaard1, James F Leckman, Helena Skyt Nielsen, Marianne Simonsen.   

Abstract

OBJECTIVE: The purpose of this article was to examine whether injuries in early childhood and gender predict prescriptions of stimulant medication in three groups of children: With attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and other psychiatric disorders (OPD).
METHODS: This was a population-based study with prospective and complete follow-up of children with ADHD (n=11,553), ASD (n=9698), and OPD (n=48,468), of whom 61%, 16%, and 3%, respectively, were treated with stimulants. For all 69,719 individual children data on psychiatric diagnoses, injuries, and drug prescriptions were obtained from national registers and merged.
RESULTS: Having sustained an injury before 5 years of age increased the likelihood of later stimulant treatment, in children with ADHD (odds ratio [OR]=1.09; 95% confidence interval [CI]=1.01-1.21), ASD (OR=1.19; 95% CI=1.02-1.40), and OPD (OR=1.24; 95% CI=1.08-1.42), with each injury increasing the likelihood by 3%, 10%, and 7%, respectively. Head injury did not increase the likelihood of later stimulant treatment. Within each of the three groups, ADHD, ASD, and OPD boys were more likely than girls to receive stimulant medication, OR=1.17 (95% CI=1.07-1.28); OR=1.71 (95% CI=1.47-2.01), and OR=2.41 (95% CI=2.16-2.71), respectively.
CONCLUSIONS: To our knowledge, this is the first prospective study assessing early life predictors of later ADHD medication in children with a psychiatric disorder, taken from a national cohort with complete follow-up of all cases. We found that the number of injuries prior to diagnosis was associated with initiation of stimulant treatment in all three groups of patients. In addition, male gender predicted treatment with ADHD medications. Our results suggest that the number of injuries early in life prior to diagnosis is associated with stimulant treatment, and may serve as a proxy for the level of later severity of ADHD symptoms, as it is universally associated with pharmacological treatment for ADHD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24813570      PMCID: PMC4064734          DOI: 10.1089/cap.2013.0101

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  47 in total

1.  Attention-deficit/hyperactivity disorder among children and adolescents in the United States: trend in diagnosis and use of pharmacotherapy by gender.

Authors:  David A Sclar; Linda M Robison; Kurt A Bowen; Jennifer M Schmidt; Leigh V Castillo; Ambartsum M Oganov
Journal:  Clin Pediatr (Phila)       Date:  2012-03-07       Impact factor: 1.168

2.  Influence of gender on attention-deficit/hyperactivity disorder in Europe--ADORE.

Authors:  Torunn Stene Nøvik; Amaia Hervas; Stephen J Ralston; Søren Dalsgaard; Rob Rodrigues Pereira; Maria J Lorenzo
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 4.785

Review 3.  Gender differences in attention-deficit/hyperactivity disorder.

Authors:  Julia J Rucklidge
Journal:  Psychiatr Clin North Am       Date:  2010-06

4.  The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.

Authors:  Hui-Chu Lang; Richard M Scheffler; Teh-Wei Hu
Journal:  Health Policy       Date:  2010-04-10       Impact factor: 2.980

5.  Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder.

Authors:  Chuan-Yu Chen; Hsueh-Han Yeh; Kuang-Hung Chen; I-Shou Chang; Erin Chia-Hsuan Wu; Keh-Ming Lin
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-06       Impact factor: 2.576

6.  Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children.

Authors:  Harvey Levin; Gerri Hanten; Jeffrey Max; Xiaoqi Li; Paul Swank; Linda Ewing-Cobbs; Maureen Dennis; Deleene S Menefee; Russell Schachar
Journal:  J Dev Behav Pediatr       Date:  2007-04       Impact factor: 2.225

7.  The Danish Psychiatric Central Research Register.

Authors:  Ole Mors; Gurli P Perto; Preben Bo Mortensen
Journal:  Scand J Public Health       Date:  2011-07       Impact factor: 3.021

8.  Coffee consumption during pregnancy and the risk of hyperkinetic disorder and ADHD: a prospective cohort study.

Authors:  Karen Markussen Linnet; Kirsten Wisborg; Niels Jørgen Secher; Per Hove Thomsen; Carsten Obel; Søren Dalsgaard; Tine Brink Henriksen
Journal:  Acta Paediatr       Date:  2008-09-01       Impact factor: 2.299

9.  Association between ADHD drug use and injuries among children and adolescents.

Authors:  Els van den Ban; Patrick Souverein; Willemijn Meijer; Herman van Engeland; Hanna Swaab; Toine Egberts; Eibert Heerdink
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-06-04       Impact factor: 4.785

10.  Attention deficit hyperactivity disorder and increased risk of injury.

Authors:  R M Merrill; J L Lyon; R K Baker; L H Gren
Journal:  Adv Med Sci       Date:  2009       Impact factor: 3.287

View more
  9 in total

1.  Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.

Authors:  Søren Dalsgaard; Anette Primdal Kvist; James F Leckman; Helena Skyt Nielsen; Marianne Simonsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-06-23       Impact factor: 2.576

2.  Understanding the Diversity of Pharmacotherapeutic Management of ADHD With Co-occurring Autism: An Australian Cross-Sectional Survey.

Authors:  Olivia J Mellahn; Rachael Knott; Jeggan Tiego; Kathryn Kallady; Katrina Williams; Mark A Bellgrove; Beth P Johnson
Journal:  Front Psychiatry       Date:  2022-06-27       Impact factor: 5.435

3.  Diversion of ADHD Stimulants and Victimization Among Adolescents.

Authors:  Quyen M Epstein-Ngo; Sean Esteban McCabe; Philip T Veliz; Sarah A Stoddard; Elizabeth A Austic; Carol J Boyd
Journal:  J Pediatr Psychol       Date:  2015-11-19

Review 4.  Problematic Peer Functioning in Girls with ADHD: A Systematic Literature Review.

Authors:  Francien M Kok; Yvonne Groen; Anselm B M Fuermaier; Oliver Tucha
Journal:  PLoS One       Date:  2016-11-21       Impact factor: 3.240

5.  Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: protocol for a systematic review and meta-analysis.

Authors:  Maite Ruiz-Goikoetxea; Samuele Cortese; Maite Aznarez-Sanado; Sara Magallon; Elkin O Luis; Noelia Álvarez Zallo; Pilar de Castro-Manglano; Cesar Soutullo; Gonzalo Arrondo
Journal:  BMJ Open       Date:  2017-09-25       Impact factor: 2.692

6.  Time of onset and/or diagnosis of ADHD in European children: a systematic review.

Authors:  Ilaria Rocco; Barbara Corso; Maurizio Bonati; Nadia Minicuci
Journal:  BMC Psychiatry       Date:  2021-11-16       Impact factor: 3.630

7.  Pediatric use of prescribed melatonin in Sweden 2006-2017: a register based study.

Authors:  Elin E Kimland; Carola Bardage; Julius Collin; Anders Järleborg; Rickard Ljung; Anastasia N Iliadou
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-07-22       Impact factor: 4.785

Review 8.  Gender Trends in Psychotropic Medication Use in Autism.

Authors:  Christopher R Huber; Zachary Fanaro; Varun Soti
Journal:  Cureus       Date:  2022-06-30

9.  Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women.

Authors:  Susan Young; Nicoletta Adamo; Bryndís Björk Ásgeirsdóttir; Polly Branney; Michelle Beckett; William Colley; Sally Cubbin; Quinton Deeley; Emad Farrag; Gisli Gudjonsson; Peter Hill; Jack Hollingdale; Ozge Kilic; Tony Lloyd; Peter Mason; Eleni Paliokosta; Sri Perecherla; Jane Sedgwick; Caroline Skirrow; Kevin Tierney; Kobus van Rensburg; Emma Woodhouse
Journal:  BMC Psychiatry       Date:  2020-08-12       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.